SCHEDULE 13G: Biotechnology Value Fund Group Discloses 7.5% Passive Stake in Kura Oncology, Inc.

A group of investment entities led by Mark N. Lampert, including Biotechnology Value Fund L.P., has reported a 7.5% passive beneficial ownership stake in Kura Oncology, Inc. as of January 27, 2025.

Summary

• The filing identifies a group of Reporting Persons, including Biotechnology Value Fund L.P., BVF I GP LLC, Biotechnology Value Fund II L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert.
• The issuer is Kura Oncology, Inc., with its Common Stock, par value $0.0001 per share, being the class of securities reported.
• As of January 27, 2025, the aggregate beneficial ownership by the group (Mark N. Lampert, BVF Partners L.P., and BVF Inc.) is 5,912,554 shares of Kura Oncology, Inc. Common Stock.
• This aggregate ownership represents approximately 7.5% of Kura Oncology, Inc.'s outstanding shares.
• The beneficial ownership includes 840,585 shares underlying Pre-Funded Warrants, which are exercisable at $0.0001 per share and do not expire.
• A 9.99% beneficial ownership blocker applies to the Pre-Funded Warrants, meaning they cannot be exercised if it would result in ownership exceeding this threshold, though the document states this limit did not apply as of the filing date.
• The filing is a Schedule 13G, indicating that the securities were acquired and are held for passive investment purposes, without the intent to change or influence the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive investment by a specialized fund, which can be seen as a positive signal of confidence in the issuer. However, it provides no new operational or financial information about the issuer itself, so the sentiment is neutral to slightly positive from the perspective of the issuer's stock.

Positives

• A significant institutional investor group, Biotechnology Value Fund, has taken a substantial passive stake, potentially signaling confidence in Kura Oncology, Inc.'s long-term prospects.
• The inclusion of Pre-Funded Warrants with a very low exercise price ($0.0001) and no expiry provides the investor group with flexible, long-term exposure to Kura Oncology, Inc.'s stock.

Risks

• The 9.99% beneficial ownership blocker on Pre-Funded Warrants could limit the immediate exercise of all warrants if it would push the holder's ownership above that threshold, although the document states this limit was not active as of the filing date.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Kura Oncology, Inc. or the reporting persons regarding the issuer's future performance or strategic direction, beyond the passive investment intent.

Management Comments

• The filing includes a certification by Mark N. Lampert on behalf of the reporting persons stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Kura Oncology, Inc., and were not acquired or held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

The acquisition of a significant passive stake by a specialized biotechnology investment fund like Biotechnology Value Fund in Kura Oncology, Inc., a company in the oncology space, suggests potential investor interest in the biotech sector, particularly in companies with promising pipelines or strategic positions. This type of filing is common for institutional investors accumulating positions.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure of beneficial ownership by a passive investor group. It does not provide financial results or operational metrics for Kura Oncology, Inc. that would allow for a direct comparison to industry standards or specific comparable companies/projects. The significance lies in the identity of the investor and the size of the stake, which is a common practice for institutional funds investing in public companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a large passive investor group may influence strategic decisions, though the filing explicitly states no intent to influence control.

Next Steps

• The reporting persons will continue to monitor their investment in Kura Oncology, Inc. and may file amendments to this Schedule 13G if their beneficial ownership percentage changes significantly (e.g., crosses a 1% threshold up or down) or if their investment intent changes from passive to active.

Key Dates

Keywords

Kura Oncology, Biotechnology Value Fund, Mark N. Lampert, Schedule 13G, Beneficial Ownership, Passive Investment, Common Stock, Pre-Funded Warrants, SEC Filing, Institutional Investor, Biotech, Oncology